Zentalis Competitors

ZNTL Stock

USD 18.58 0.13 0.70%

Zentalis PharmaceuticalsL competes with Siriuspoint, ESGEN Acquisition, Ping An, Palomar Holdings, and Kingsway Financial; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Zentalis PharmaceuticalsL competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Zentalis PharmaceuticalsL to its intrinsic valuation because they are able to contrast its competitors on a relative basis.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Zentalis PharmaceuticalsL competition on your existing holdings. Check out Zentalis PharmaceuticalsL Correlation with its peers.

The value of Return on Average Assets is estimated to slide to -0.5. The value of Return on Average Equity is estimated to slide to -0.59. Tangible Assets Book Value per Share is expected to rise to 11.72 this year, although the value of Total Assets will most likely fall to about 456.1 M.

Specify up to 10 symbols:

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Zentalis PharmaceuticalsL's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Zentalis PharmaceuticalsL in the context of predictive analytics.

Hype

Prediction

Low	Estimated Value	High
14.54	18.69	22.84

Details

Intrinsic

Valuation

Low	Real Value	High
16.72	26.96	31.11

Details

Naive

Forecast

Low	Next Value	High
13.89	18.05	22.20

Details

10 Analysts

Consensus

Low	Target Price	High
27.00	51.11	120.00

Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Zentalis PharmaceuticalsL. Your research has to be compared to or analyzed against Zentalis PharmaceuticalsL's peers to derive any actionable benefits. When done correctly, Zentalis PharmaceuticalsL's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Zentalis PharmaceuticalsL.

Zentalis PharmaceuticalsL Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Zentalis PharmaceuticalsL and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Zentalis and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Zentalis PharmaceuticalsL does not affect the price movement of the other competitor.

Related Correlations

	SPNT	ESAC	PIAIF	PLMR	KFS	PPYA	UVE
SPNT		0.81	0.28	0.64	0.74	0.81	0.66	SPNT
ESAC	0.81		-0.05	0.74	0.82	0.84	0.81	ESAC
PIAIF	0.28	-0.05		0.06	0.03	0.15	-0.2	PIAIF
PLMR	0.64	0.74	0.06		0.82	0.77	0.76	PLMR
KFS	0.74	0.82	0.03	0.82		0.85	0.76	KFS
PPYA	0.81	0.84	0.15	0.77	0.85		0.85	PPYA
UVE	0.66	0.81	-0.2	0.76	0.76	0.85		UVE
	SPNT	ESAC	PIAIF	PLMR	KFS	PPYA	UVE

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Risk-Adjusted Indicators

Nowadays, there is a big difference between Zentalis Stock performing well and Zentalis PharmaceuticalsL company doing well compared to the competition. There are way too many exceptions to the normal that investors can tell for sure what's good or bad unless they analyze Zentalis PharmaceuticalsL's multiple risk-adjusted performance indicators. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Information Ratio	Expected Shortfall	Potential Upside	Value At Risk	Maximum Drawdown
SPNT	1.72	0.43	0.20	0.31	1.79	0.19	(1.93)	3.74	(3.73)	11.56	Siriuspoint Profile Siriuspoint Dashboard Technical analysis Backtest News Timeline Fundamentals Trends
ESAC	0.16	0.02	0.16	0.27	0.22	0.23	(0.27)	0.38	(0.19)	3.42	ESGEN Acquisition Profile ESGEN Acquisition Dashboard Technical analysis Backtest News Timeline Fundamentals Trends
PIAIF	1.41	0.01	0.02	(0.08)	2.23	0.0329	(2.36)	4.28	(4.65)	14.51	Ping An Profile Ping An Dashboard Technical analysis Backtest
PLMR	2.08	0.27	0.09	0.17	2.76	0.09	(2.06)	4.62	(4.98)	16.32	Palomar Holdings Profile Palomar Holdings Dashboard Technical analysis Backtest News Timeline Analyst Consensus Fundamentals Trends
KFS	1.84	0.36	0.15	0.58	2.20	0.15	(2.11)	3.80	(3.45)	17.93	Kingsway Financial Profile Kingsway Financial Dashboard Technical analysis Backtest News Timeline Fundamentals Trends
PPYA	0.07	0.03	0.00	21.22	0.00	0.81	0.00	0.20	(0.10)	0.59	Papaya Growth Profile Papaya Growth Dashboard Technical analysis Backtest News Timeline Fundamentals Trends
UVE	2.53	1.20	0.56	0.87	1.37	0.27	(3.23)	6.13	(3.26)	26.98	Universal Insurance Profile Universal Insurance Dashboard Technical analysis Backtest News Timeline Analyst Consensus Fundamentals Trends

Cross Equities Net Income Analysis

Compare Zentalis PharmaceuticalsL and related stocks such as Siriuspoint, ESGEN Acquisition Corp, Ping An Insurance, Palomar Holdings, Kingsway Financial, Papaya Growth Opportunity, and Universal Insurance Net Income Over Time

Select Fundamental

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

SPNT

99.4 M

227.3 M

50.4 M

(87.4 M)

27.6 M

277.8 M

(317.7 M)

200.6 M

143.5 M

58.1 M

(386.8 M)

(397 M)

ESAC

9.5 M

8.5 M

PLMR

6.6 M

3.8 M

18.2 M

10.6 M

6.3 M

45.8 M

52.2 M

56.3 M

KFS

(52.1 M)

(36.9 M)

(12.8 M)

1.1 M

803 K

(15.7 M)

(30.1 M)

(5.9 M)

(6.7 M)

(342 K)

24.7 M

26.7 M

PPYA

(33 K)

(29.7 K)

(32 K)

UVE

30.3 M

59 M

73 M

106.5 M

99.4 M

106.9 M

117.1 M

46.5 M

19.1 M

20.4 M

(22.3 M)

(22.8 M)

Zentalis PharmaceuticalsL and related stocks such as Siriuspoint, ESGEN Acquisition Corp, Ping An Insurance, Palomar Holdings, Kingsway Financial, Papaya Growth Opportunity, and Universal Insurance Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Zentalis PharmaceuticalsL financial statement analysis. It represents the amount of money remaining after all of Zentalis PharmaceuticalsLlc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income to Non Controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends.

Zentalis PharmaceuticalsL Competitive Analysis

The better you understand Zentalis PharmaceuticalsL competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Zentalis PharmaceuticalsL's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Zentalis PharmaceuticalsL's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	ZNTL	SPNT	ESAC	PIAIF	PLMR	KFS	PPYA	UVE
	0.70 18.58 Zentalis	2.05 7.47 Siriuspoint	0.38 10.50 ESGEN	0.94 6.46 PIAIF	4.63 55.54 Palomar	0.89 8.93 Kingsway	0.1 10.39 Papaya	1.93 19.01 Universal
Market Volatility (90 Days Market Risk)	Not too volatile	Somewhat reliable	Very steady	Somewhat reliable	Very steady	Somewhat reliable	Very steady	Not too volatile
Market Performance (90 Days Performance)	Weak	OK	Modest	Weak	OK	OK	Strong	Solid
Odds of Financial Distress (Probability Of Bankruptcy)	Low	Below Average	Average	Close to Average	Low	Average	Below Average	Low
Current Valuation (Equity Enterprise Value)	Under Valued	Under Valued	Fairly Valued	Over Valued	Under Valued	Under Valued	Under Valued	Fairly Valued
Buy or Sell Advice (Average Analysts Consensus)	Strong Buy	Hold	Not Available	Not Available	Buy	Not Available	Not Available	Buy
Trade Advice (90 Days Macroaxis Advice)	Strong Hold	Strong Buy	Strong Hold	Strong Sell	Buy	Strong Buy	Strong Buy	Strong Buy
Number of Shares Shorted	8.01 M	1.59 M	4.84 K	N/A	643.17 K	295.4 K	1.63 K	598.58 K
Shares Owned by Insiders	4.18 %	12.66 %	N/A	16.00 %	4.47 %	30.35 %	N/A	10.21 %
Current Ratio	9.61 X	3.31 X	3.09 X	6.18 X	0.51 X	0.92 X	0.08 X	0.66 X
Net Asset	539.31 M	11.04 B	N/A	10142.03 B	1.3 B	285.65 M	N/A	2.89 B
Profit Margin	N/A	(0.18) %	N/A	0.08 %	0.16 %	0.26 %	N/A	(0.0182) %
EBITDA	(225.86 M)	(336.6 M)	N/A	162.51 B	74.15 M	44.02 M	N/A	(5.22 M)
Current Valuation	720.73 M	1.37 B	353.6 M	235.35 B	1.31 B	414.11 M	382.21 M	140.38 M
Cash Flow from Operations	(163.75 M)	293.3 M	(1.41 M)	90.12 B	169.58 M	(2.63 M)	79.56 K	324.51 M
Operating Margin	N/A	(0.20) %	N/A	0.12 %	0.21 %	0.0014 %	N/A	(0.0169) %
Retained Earnings	N/A	N/A	N/A	180.4 B	N/A	(371.13 M)	N/A	370.81 M
Current Asset	N/A	N/A	N/A	909.92 B	N/A	N/A	N/A	N/A
Five Year Return	N/A	N/A	N/A	2.85 %	N/A	N/A	N/A	3.27 %
Beta	1.87	0.99	N/A	1.0	0.0568	-0.26	N/A	0.91
Price to Book	2.66 X	0.53 X	N/A	1.02 X	3.56 X	6.03 X	N/A	1.31 X
Shares Outstanding	59.42 M	162.38 M	27.6 M	7.45 B	24.98 M	25.05 M	30.12 M	30.43 M
Annual Yield	N/A	0.20 %	N/A	0.0487 %	N/A	N/A	N/A	0.0356 %
Total Debt	46.8 M	778 M	171.35 K	1458.37 B	47.08 M	34.28 M	75 K	101.3 M
Return On Equity	(0.59) %	(0.17) %	N/A	0.11 %	0.13 %	1.63 %	N/A	(0.06) %
Price to Earning	N/A	3.25 X	N/A	4.92 X	253.33 X	(16.38) X	N/A	13.42 X
Z Score	13.8	0.6	N/A	N/A	18.0	2.2	N/A	3.0
Shares Owned by Institutions	95.82 %	82.60 %	100.00 %	40.76 %	99.86 %	44.98 %	87.33 %	68.70 %
Return On Asset	(0.29) %	(0.0242) %	N/A	0.0088 %	0.0383 %	0.0002 %	N/A	(0.0052) %
Book Value Per Share	7.32 X	11.68 X	(0.36) X	46.32 X	15.37 X	0.68 X	(0.33) X	9.47 X
Cash and Equivalents	455.22 M	4.34 B	947.48 K	2230 B	36.47 M	12.64 M	1.19 M	388.71 M
Price to Earnings To Growth	N/A	(0.25) X	N/A	0.44 X	0.25 X	N/A	N/A	N/A
Current Liabilities	N/A	N/A	N/A	167.2 B	N/A	N/A	N/A	N/A
Total Asset	539.31 M	11.04 B	N/A	10142.03 B	1.3 B	285.65 M	N/A	2.89 B
Short Ratio	15.42 X	4.23 X	0.38 X	N/A	3.77 X	3.99 X	0.19 X	2.27 X
Target Price	51.2	N/A	N/A	N/A	59.17	1.0	N/A	19.0
Last Dividend Paid	N/A	N/A	N/A	3.3	N/A	N/A	N/A	0.64
Market Capitalization	1.11 B	1.19 B	360.87 M	132.9 B	1.42 B	233.69 M	391.13 M	578.19 M
Price to Sales	N/A	0.54 X	N/A	0.09 X	4.05 X	1.56 X	N/A	0.25 X
Cash per Share	7.99 X	27.15 X	0.03 X	123.21 X	1.45 X	0.50 X	0.03 X	10.08 X
Net Income	(237.11 M)	(386 M)	14.19 M	101.62 B	52.17 M	15.06 M	(131.89 K)	(22.26 M)
Earnings Per Share	(4.99) X	(2.56) X	N/A	0.80 X	1.84 X	1.20 X	N/A	(0.72) X
Debt to Equity	0.1 %	0.37 %	N/A	1.81 %	0.06 %	N/A	3.12 %	0.40 %
Revenue	N/A	2.11 B	N/A	1061.76 B	327.09 M	93.28 M	N/A	1.22 B
Working Capital	N/A	N/A	N/A	742.72 B	N/A	N/A	N/A	N/A
Gross Profit	N/A	(129.2 M)	N/A	397.42 B	80.05 M	66.96 M	N/A	284.26 M
Day Typical Price	18.54	N/A	N/A	N/A	55.43	N/A	N/A	19.07
Accumulation Distribution	4795.43	N/A	N/A	N/A	526.54	N/A	N/A	1562.31
Market Facilitation Index	0.0	N/A	N/A	N/A	1.0E-4	N/A	N/A	0.0
Daily Balance Of Power	0.1625	N/A	N/A	N/A	1.983871	N/A	N/A	0.75
Rate Of Daily Change	1.01	N/A	N/A	N/A	1.05	N/A	N/A	1.02
Day Median Price	18.52	N/A	N/A	N/A	55.38	N/A	N/A	19.1
Price Action Indicator	0.12	N/A	N/A	N/A	1.39	N/A	N/A	0.09
Coefficient Of Variation	(8,883)	593.63	1129.61	7051.04	1353.0	774.32	283.53	378.96
Mean Deviation	2.86	1.72	0.1609	1.41	2.08	1.84	0.0673	2.53
Jensen Alpha	0.0083	0.4264	0.0238	0.0064	0.2688	0.3617	0.0255	1.2
Total Risk Alpha	0.1784	0.4889	0.039	0.1663	0.3662	0.4815	0.0313	1.37
Sortino Ratio	N/A	0.2031	0.1606	0.0208	0.0856	0.1545	N/A	0.5572
Downside Variance	N/A	4.23	0.222	15.06	9.03	6.23	N/A	4.5
Standard Deviation	4.06	2.21	0.3355	2.46	2.86	2.63	0.1006	4.31
Kurtosis	2.14	0.5526	19.72	3.16	1.36	3.08	7.51	12.22
Potential Upside	5.07	3.74	0.3824	4.28	4.62	3.8	0.1951	6.13
Treynor Ratio	(0.048718)	0.3126	0.2687	(0.08)	0.1671	0.5803	21.22	0.868
Maximum Drawdown	22.62	11.56	3.42	14.51	16.32	17.93	0.5875	26.98
Variance	16.51	4.87	0.1125	6.03	8.18	6.93	0.0101	18.54
Market Risk Adjusted Performance	(0.038718)	0.3226	0.2787	(0.07)	0.1771	0.5903	21.23	0.878
Risk Adjusted Performance	(0.003318)	0.1691	0.067	0.0198	0.0784	0.1317	0.2558	0.2639
Skewness	0.0632	0.1795	(0.08)	(0.85)	0.1673	0.0319	2.16	2.99
Semi Deviation	N/A	1.79	0.2169	2.23	2.76	2.2	N/A	1.37
Information Ratio	1.0E-4	0.1893	0.2255	0.0329	0.09	0.1466	0.8097	0.2746
Value At Risk	(6.11)	(3.73)	(0.19)	(4.65)	(4.98)	(3.45)	(0.1)	(3.26)
Expected Short fall	N/A	(1.93)	(0.27)	(2.36)	(2.06)	(2.11)	N/A	(3.23)
Downside Deviation	N/A	2.06	0.4711	3.88	3.0	2.5	N/A	2.12
Semi Variance	N/A	3.19	0.047	4.98	7.61	4.82	N/A	1.87

Zentalis PharmaceuticalsL Competition Performance Charts

Five steps to successful analysis of Zentalis PharmaceuticalsL Competition

Zentalis PharmaceuticalsL's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Zentalis PharmaceuticalsL in relation to its competition. Zentalis PharmaceuticalsL's competition analysis typically involves several steps, including::

Identifying the key players in the market: This involves identifying the major competitors of Zentalis PharmaceuticalsL in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Zentalis PharmaceuticalsL's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Zentalis PharmaceuticalsL, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Zentalis PharmaceuticalsL position

In addition to having Zentalis PharmaceuticalsL in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Industrial Metal Mining Thematic Idea Now

Industrial Metal Mining

Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Industrial Metal Mining theme has 61 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Industrial Metal Mining Theme or any other thematic opportunities.

View All Next

Launch

Check out Zentalis PharmaceuticalsL Correlation with its peers. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for analysis

When running Zentalis PharmaceuticalsL price analysis, check to measure Zentalis PharmaceuticalsL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zentalis PharmaceuticalsL is operating at the current time. Most of Zentalis PharmaceuticalsL's value examination focuses on studying past and present price action to predict the probability of Zentalis PharmaceuticalsL's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Zentalis PharmaceuticalsL's price. Additionally, you may evaluate how the addition of Zentalis PharmaceuticalsL to your portfolios can decrease your overall portfolio volatility.

	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	ETF Directory Find actively traded Exchange Traded Funds (ETF) from around the world
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Price Transformation Use Price Transformation models to analyze depth of different equity instruments across global markets
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Equity Valuation Check real value of public entities based on technical and fundamental data

Is Zentalis PharmaceuticalsL's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis PharmaceuticalsL. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis PharmaceuticalsL listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.99)

Return On Assets

(0.29)

Return On Equity

(0.59)

The market value of Zentalis PharmaceuticalsL is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis PharmaceuticalsL's value that differs from its market value or its book value, called intrinsic value, which is Zentalis PharmaceuticalsL's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis PharmaceuticalsL's market value can be influenced by many factors that don't directly affect Zentalis PharmaceuticalsL's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Zentalis PharmaceuticalsL's value and its price as these two are different measures arrived at by different means. Investors typically determine Zentalis PharmaceuticalsL value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis PharmaceuticalsL's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC

Working Capital	Tangible Assets Book Value per Share
Tangible Asset Value	Sales per Share
Return on Sales	Return on Invested Capital
Return on Average Equity	Return on Average Assets
Price to Sales Ratio	Price Sales Damodaran Method
Price to Earnings Ratio	Price Earnings Damodaran Method
Price to Book Value	Payout Ratio
Profit Margin	Market Capitalization
Invested Capital Average	Invested Capital
Gross Margin	Foreign Currency to USD Exchange Rate
Free Cash Flow per Share	Free Cash Flow
Enterprise Value over EBITDA	Enterprise Value over EBIT
Enterprise Value	Average Equity
Earnings per Basic Share USD	Earnings per Diluted Share
Earnings per Basic Share	Earnings before Tax
Earnings Before Interest Taxes and Depreciation Amortization USD	EBITDA Margin
Earnings Before Interest Taxes and Depreciation Amortization EBITDA	Dividends per Basic Common Share
Dividend Yield	Debt to Equity Ratio
Current Ratio	Book Value per Share
Asset Turnover	Average Assets
Total Assets Per Share	Net Assets Per Share
Cash Flow Per Share	Revenue Per Employee
Net Income Per Employee	Return on Investment
Operating Margin	Calculated Tax Rate
Receivables Turnover	Inventory Turnover
PPandE Turnover	Cash and Equivalents Turnover
Accounts Payable Turnover	Accrued Expenses Turnover
Interest Coverage	Long Term Debt to Equity
Quick Ratio	Net Current Assets as percentage of Total Assets
Revenue to Assets

Zentalis Competitors

Specify up to 10 symbols:

Zentalis PharmaceuticalsL Competition Correlation Matrix

Related Correlations

Risk-Adjusted Indicators

Cross Equities Net Income Analysis

Zentalis PharmaceuticalsL and related stocks such as Siriuspoint, ESGEN Acquisition Corp, Ping An Insurance, Palomar Holdings, Kingsway Financial, Papaya Growth Opportunity, and Universal Insurance Net Income description

Zentalis PharmaceuticalsL Competitive Analysis

Zentalis PharmaceuticalsL Competition Performance Charts

Five steps to successful analysis of Zentalis PharmaceuticalsL Competition

Complement your Zentalis PharmaceuticalsL position

Did You Try This Idea?

Run Industrial Metal Mining Thematic Idea Now

Industrial Metal Mining

Complementary Tools for analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY